Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

Double-Blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-Experienced Subjects.

The purpose of this research study is to determine which of three different dose combinations of tipranavir and ritonavir, when taken with a standard approved anti-HIV drug therapy, is most effective and safe. Tipranavir is an investigational protease inhibitor which has been demonstrated to have in vitro activity against HIV-1.

Study Overview

• Status: Completed
• Conditions: HIV Infections
• Intervention / Treatment: Drug: Protease inhibitor tipranavir

Detailed Description

This study will be conducted in HIV+, multiple ARV medication experienced patients. All patients must have received treatment from each of three ARV classes: NRTIs, NNRTIs and PIs, have received at least two PI-based ARV regimens (may include the current regimen) with a viral load greater than or equal to 1000 copies/mL at the time of study entry. The two separate PI-based regimens must each have been taken for at least 3 months. At least one resistance-conferring PI-mutation (from a pre-established panel) must be present. Baseline genotypic screening will be performed and will be used in conjunction with ARV medication history to determine new background therapy for each individual subject to use.

Following genotypic screening at baseline, qualifying subjects will be randomized to one of three blinded treatment regimens. Subjects will discontinue their current protease inhibitor and initiate TPV/RTV for 2 weeks of functional monotherapy. Thereafter, the background ARV medications will be optimized and subjects will remain on blinded TPV/RTV plus optimized background therapy for the duration of the trial. Trial duration ranges between 12-32 weeks, depending on when the subject is entered into the trial and the interim analyses for determination of optimized TPV/RTV regimen is completed. On determination of the optimal TPV/RTV dose, subjects may opt to continue open-label treatment.

• Study Type: Interventional
• Enrollment: 165
• Phase: Phase 2

Contacts and Locations

Study Locations

• Puerto Rico
  • San Juan, Puerto Rico, 00923
    • Clinical Research Puerto Rico
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85006
      • Phoenix Body Positive
  • California
    • Fountain Valley, California, United States, 92708
      • Orange County Center for Special Immunology
    • Long Beach, California, United States, 90813
      • Living Hope Clinical Trials Inc.
    • Los Angeles, California, United States, 90095
      • University of California, Los Angeles Medical Center
    • Los Angeles, California, United States, 90027
      • AHF Research Center
    • Los Angeles, California, United States, 90033
      • University of So. California / LA County USC Medical Center
    • Los Angeles, California, United States, 90046
      • ID Care, Inc.
    • Los Angeles, California, United States, 90048
      • Tower I.D. Medical Assoc., Inc.
    • San Francisco, California, United States, 94110
      • University of California San Francisco Positive Health Program Research
    • San Francisco, California, United States, 94115
      • Pacific Horizon Medial Group
  • District of Columbia
    • Washington, District of Columbia, United States, 20007
      • Georgetown University Medical Center
    • Washington, District of Columbia, United States, 20009
      • Dupont Circle Physicians Group
  • Florida
    • Altamonte Springs, Florida, United States, 32701
      • (IDC) Research Institute
    • Fort Lauderdale, Florida, United States, 33308
      • Therafirst Medical Center
    • Miami, Florida, United States, 33136
      • Jackson Medical Tower
    • South Miami, Florida, United States, 33133
      • Steinhart Medical Associates
    • Tampa, Florida, United States, 33602
      • Hillsborough County Health Dept.
    • Vero Beach, Florida, United States, 32960
      • Treasure Coast Infectious Disease Consultants
  • Georgia
    • Atlanta, Georgia, United States, 30308
      • AIDS Research Consortium of Atlanta
    • Decatur, Georgia, United States, 30033
      • Atlanta VA Medical Center, Dept. of ID
    • Macon, Georgia, United States, 31207
      • Mercer University School of Medicine
  • Illinois
    • Chicago, Illinois, United States, 60612
      • CORE Center, Cook County Hospital
    • Chicago, Illinois, United States, 60612
      • Rush Presbyterian/St. Luke's Medical Center
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • University of Louisville
  • Louisiana
    • New Orleans, Louisiana, United States, 70112
      • HIV Outpatient Program (H.O.P.)
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • John's Hopkins University School of Medicine
  • Massachusetts
    • Boston, Massachusetts, United States, 02125
      • Community Research Initiative of New England
    • Springfield, Massachusetts, United States, 01107
      • CRI Community Research Initiative
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Health System
    • Detroit, Michigan, United States, 48202
      • Henry Ford Hospital, Infectious Diseases Dept.
  • Missouri
    • Kansas City, Missouri, United States, 64111
      • Kansas City Free Health Clinic
    • St. Louis, Missouri, United States, 63108
      • Washington University AIDS Clinical Trial Unit
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Wellness Center
  • New Jersey
    • Hillsborough, New Jersey, United States, 08844
      • ID Care, Inc.
    • Randolph, New Jersey, United States, 07869
      • ID Care, Inc.
  • New Mexico
    • Santa Fe, New Mexico, United States, 97505
      • Southwest CARE Center
  • New York
    • Albany, New York, United States, 12208
      • Albany Medical College
    • New York, New York, United States, 10029
      • Mount Sinai School of Medicine
    • Stony Brook, New York, United States, 11794
      • University of New York at Stony Brook
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • University of North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University Medical Center Infectious Diseases Clinic
    • Huntersville, North Carolina, United States, 28078
      • Jemsek Clinic
    • Winston Salem, North Carolina, United States, 27157
      • Wake Forest University Baptist Medical Center
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Ohio State University Medical Center
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Infect. Disease Institute, Clinical Trials Unit
  • South Carolina
    • Columbia, South Carolina, United States, 29206
      • Burnside Clinic
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Vanderbilt University - AIDS Clinical Trial Unit
  • Texas
    • Dallas, Texas, United States, 75219
      • Nelson-Tebedo Clinic
    • Houston, Texas, United States, 77004
      • Gathe Clinic
  • Virginia
    • Annandale, Virginia, United States, 22003
      • Infectious Disease Physicians Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Signed informed consent prior to trial participation.
2. HIV-1 infected males or females >= 18 years of age.
3. At least 3 months experience taking NRTIs, NNRTI(s), and PIs.
4. Current PI-based ARV medication regimen for at least 3 months prior to randomization, and at least 3 months experience taking at least one other PI-based regimen.
5. HIV-1 viral load >= 1000 copies/mL at screening.
6. Genotypic resistance report indicating one or more primary PI resistance mutation(s), including 30N, 46I/L, 48V, 50V, 82A/F/T, 84V or 90M, with not more than one of 82 A/F/T or 84V or 90M.
7. Acceptable screening laboratory values that indicate adequate baseline organ function. Laboratory values are considered to be acceptable if severity is no higher than Grade 3 GGT, Grade 2 cholesterol or triglycerides, and no higher than Grade 1 for all other tests based on the DAIDS Grading Scale. All laboratory values outside these limits are subject to approval by BI.
8. Acceptable medical history, as assessed by the investigator, with chest X-ray and ECG within 1 year of study participation.
9. Willingness to abstain from ingesting substances which may alter plasma study drug levels by interaction with the cytochrome P450 system, such as: grapefruit or Seville oranges or their products; herbal preparations containing St. John's Wort or milk thistle, and garlic supplements.
10. A prior AIDS defining event is acceptable as long as it has resolved or the subject has been on stable treatment for at least 2 months.

Exclusion Criteria:

1. ARV medication naïve.

2. Female subjects who:

   • have a positive serum pregnancy test at screening or during the study
   • are breast feeding
   • are planning to become pregnant
   • are not willing to use two barrier methods of contraception (e.g. latex condom plus spermicidal jelly/foam).
3. Any active opportunistic infection within 60 days before study entry.
4. Active Hepatitis B or C disease defined as HBsAg positive or HCV RNA positive with AST/ALT >Grade 1.
5. Prior tipranavir use.
6. Use of investigational medications within 30 days before study entry or during the trial. Some expanded access drugs may be acceptable; must be approved by BI. Tenofovir, investigational at time of preparation of this protocol, is acceptable.
7. Use of concomitant drugs which may significantly reduce plasma levels of the study medications.
8. Use of immunomodulatory drugs (e.g. interferon, cyclosporin, hydroxyurea, interleukin-2).
9. Active substance abuse.
10. Inability to swallow TPV or RTV capsules.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Study record dates

Study Major Dates

• Study Start: April 1, 2002
• Study Completion: October 1, 2002

Study Registration Dates

• First Submitted: May 2, 2002
• First Submitted That Met QC Criteria: May 2, 2002
• First Posted (ESTIMATE): May 3, 2002

Study Record Updates

• Last Update Posted (ESTIMATE): September 20, 2005
• Last Update Submitted That Met QC Criteria: September 19, 2005
• Last Verified: September 1, 2005

More Information

Terms related to this study

• Keywords: HIV; treatment experienced; ritonavir; Boehringer; tipranavir
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; HIV Infections; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Viral Protease Inhibitors; Protease Inhibitors; Tipranavir; HIV Protease Inhibitors
• Other Study ID Numbers: BI 1182.52